The addressable market for xphozah is 400,000 patients. If we reach half that number (200,000) and the price is the same as it is for IBS-C of about 20k per year, then that's 4 billion per year peak sales. Add in 500 million for the IBS-C indication to give us 4.5 billion per year, almost 8x the current market cap. Mid 20's for a conservative sp and a buyout should be much higher, at 3x peak sales I could see a buyout in the 70's.
News 
Market Data 
Discover 
